These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1163833)

  • 1. Alteration of warfarin kinetics in man associated with exposure to an operating-room environment.
    Ghoneim MM; Delle M; Wilson WR; Ambre JJ
    Anesthesiology; 1975 Sep; 43(3):333-6. PubMed ID: 1163833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of furosemide and bumetanide on warfarin metabolism and anticoagulant response.
    Nilsson CM; Horton ES; Robinson DS
    J Clin Pharmacol; 1978; 18(2-3):91-4. PubMed ID: 624779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin in the dog: pharmacokinetics as related to clinical response.
    Neff-Davis CA; Davis LE; Gillette EL
    J Vet Pharmacol Ther; 1981 Jun; 4(2):135-40. PubMed ID: 7349326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin elimination and responsiveness in patients with renal dysfunction.
    Bachmann K; Shapiro R; Mackiewicz J
    J Clin Pharmacol; 1977; 17(5-6):292-9. PubMed ID: 858804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced elimination of warfarin during treatment with cholestyramine.
    Jähnchen E; Meinertz T; Gilfrich HJ; Kersting F; Groth U
    Br J Clin Pharmacol; 1978 May; 5(5):437-40. PubMed ID: 656283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
    Holford NH
    Clin Pharmacokinet; 1986; 11(6):483-504. PubMed ID: 3542339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cimetidine: interaction with oral anticoagulants in man.
    Serlin MJ; Sibeon RG; Mossman S; Breckenridge AM; Williams JR; Atwood JL; Willoughby JM
    Lancet; 1979 Aug; 2(8138):317-9. PubMed ID: 89387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.
    O'Reilly RA; Aggeler PM
    Circulation; 1968 Jul; 38(1):169-77. PubMed ID: 11712286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasma half-lives of the enantiomers of warfarin in warfarin-resistant and warfarin-susceptible rats.
    Hewick DS
    J Pharm Pharmacol; 1972 Aug; 24(8):661-2. PubMed ID: 4403752
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.
    Williams RL; Schary WL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1976 Jul; 20(1):90-7. PubMed ID: 1277729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary excretion of warfarin in rabbits: relationship between pharmacological effect and salivary pharmacokinetics of warfarin in rabbits.
    Sakai K; Nishiura A; Fujihara Y; Kutsuna T; Nishino T
    J Pharmacobiodyn; 1983 Dec; 6(12):991-9. PubMed ID: 6674482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin pharmacokinetics in the horse.
    Thijssen HH; van den Bogaard AE; Wetzel JM; Maes JH; Muller AP
    Am J Vet Res; 1983 Jul; 44(7):1192-6. PubMed ID: 6881659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
    Oberwittler H; Hirschfeld-Warneken A; Wesch R; Willerich H; Teichert L; Lehr KH; Ding R; Haefeli WE; Mikus G
    J Clin Pharmacol; 2007 Jan; 47(1):70-7. PubMed ID: 17192504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking and warfarin disposition.
    Bachmann K; Shapiro R; Fulton R; Carroll FT; Sullivan TJ
    Clin Pharmacol Ther; 1979 Mar; 25(3):309-15. PubMed ID: 761442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The warfarin-sulfinpyrazone interaction: stereochemical considerations.
    Toon S; Low LK; Gibaldi M; Trager WF; O'Reilly RA; Motley CH; Goulart DA
    Clin Pharmacol Ther; 1986 Jan; 39(1):15-24. PubMed ID: 3943265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of interaction between famotidine and warfarin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; Buntinx A; Distlerath L; De Schepper PJ
    Int J Clin Pharmacol Res; 1990; 10(3):167-71. PubMed ID: 2228341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the effects of warfarin in dogs by halofenate: an influence upon the kinetics of prothrombin.
    Weintraub M; Griner PF
    Thromb Diath Haemorrh; 1975 Nov; 34(2):445-54. PubMed ID: 1198407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole potentiates warfarin-induced prothrombin time prolongation.
    Purkins L; Wood N; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):24-9. PubMed ID: 14616410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium warfarin.
    O'Reilly RA
    Pharmacology; 1972; 8(1):181-90. PubMed ID: 4644647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.